There appears to be movement in the US to bring less expensive versions of biotech drugs to market. But the brand name drug industry wants these so-called biosimilars to adhere to rigorous safety and efficacy standards currently not built into US laws. Tom DiLenge, vice president and general counsel for the Biotechnology Industry Organization, tells host Bruce Japsen about a palatable pathway biotech companies would like to see approved by Congress to bring cheaper biotech drugs to the US market.
What Biotech Companies Want in Generic Legislation
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
There appears to be movement in the US to bring less expensive versions of biotech drugs to market. But the brand name drug industry wants these so-called biosimilars to adhere to rigorous safety and efficacy standards currently not built into US laws. Tom DiLenge, vice president and general counsel for the Biotechnology Industry Organization, tells host Bruce Japsen about a palatable pathway biotech companies would like to see approved by Congress to bring cheaper biotech drugs to the US market.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Bridging Distances in PAH: Bringing Best Practices to the People Through Telementoring
Updates From the 7th World Symposium Task Force
Pulmonary Hypertension Management: Practice Trends and Updates
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
Evaluating Sleep Deprivation as a Risk Factor for Postpartum Depression
Clinical Strategies for Assessing Sleep Disturbances in Postpartum Patients
mIDH Gliomas Explained: Characteristics and Management Strategies
Improving the IUD Experience: Evidence-Based Pain Management Approaches
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?